{"entity":{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","aka":["Hansoh","Hansoh Pharma","Hansoh Pharmaceutical Group","翰森制药","hansoh"],"tldr":"Hansoh is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib (Ameile in China, Aumseqa in the EU) became the first China-originated lung cancer pill authorised by the European Commission in 2026.","summary":"Hansoh Pharmaceutical, based in Lianyungang, Jiangsu, and listed in Hong Kong as 3692.HK, is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib, sold as Ameile in China and Aumseqa in the European Union, became the first China-originated lung cancer tablet authorised by the European Commission in 2026. Aumolertinib is a third-generation EGFR kinase inhibitor approved by the NMPA in 2020 and by the EU in 2026 for EGFR-mutant non-small-cell lung cancer, and the company has out-licensed antibody-drug conjugate and GLP-1 assets to GSK and Merck. OnCo links it to the aumolertinib drug record. Whether a European approval can win share from the established third-generation EGFR drug is the open question. Aumolertinib has its own page. The B7-H4 (HS-20089) and B7-H3 (HS-20093) antibody-drug conjugates were licensed to GSK in 2023 for $85 million and $185 million upfront, and the GLP-1 agreements with Merck & Co. sit outside oncology; the company was founded in 1995 and is run by Zhong Huijuan, one of the world's wealthiest self-made women.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Hansoh_Pharmaceutical","links":[{"label":"Official website","url":"https://www.hspharm.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy","adcs"],"technologies":[],"targets":[],"drugs":["aumolertinib","hs-20093","hs-20089","hs-20117","flumatinib"],"companies":["gsk","merck"],"institutions":[],"pathways":[],"terms":[],"trials":["aeneas","nct05435248","nct07468851","nct05367778","nct06147570","nct07283367","nct04951635","nct04687241","nct05830123","nct06007729","nct04923906","nct06014190","nct06112704"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lianyungang, Jiangsu","country":"CN","companyType":"pharma","website":"https://www.hspharm.com","ticker":"3692.HK","founded":1995,"investors":[],"funding":[]},"route":"/companies/hansoh-pharma/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/"},{"id":"flumatinib","kind":"drug","name":"Flumatinib","route":"/drugs/flumatinib/"},{"id":"hs-20089","kind":"drug","name":"HS-20089","route":"/drugs/hs-20089/"},{"id":"hs-20093","kind":"drug","name":"HS-20093","route":"/drugs/hs-20093/"},{"id":"hs-20117","kind":"drug","name":"HS-20117","route":"/drugs/hs-20117/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"trial":[{"id":"nct07283367","kind":"trial","name":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","route":"/trials/nct07283367/"},{"id":"nct07824882","kind":"trial","name":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo","route":"/trials/nct07824882/"},{"id":"nct07464327","kind":"trial","name":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S","route":"/trials/nct07464327/"},{"id":"nct04951635","kind":"trial","name":"A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer","route":"/trials/nct04951635/"},{"id":"nct07822542","kind":"trial","name":"A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat","route":"/trials/nct07822542/"},{"id":"nct06147570","kind":"trial","name":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","route":"/trials/nct06147570/"},{"id":"nct07468851","kind":"trial","name":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","route":"/trials/nct07468851/"},{"id":"nct06526624","kind":"trial","name":"A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer","route":"/trials/nct06526624/"},{"id":"nct06417008","kind":"trial","name":"A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct06417008/"},{"id":"aeneas","kind":"trial","name":"AENEAS","route":"/trials/aeneas/"},{"id":"nct04687241","kind":"trial","name":"Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations","route":"/trials/nct04687241/"},{"id":"nct05830123","kind":"trial","name":"ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas","route":"/trials/nct05830123/"},{"id":"nct06007729","kind":"trial","name":"ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","route":"/trials/nct06007729/"},{"id":"nct06498479","kind":"trial","name":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06498479/"},{"id":"nct04923906","kind":"trial","name":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut","route":"/trials/nct04923906/"},{"id":"nct06855069","kind":"trial","name":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06855069/"},{"id":"nct06014190","kind":"trial","name":"HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer","route":"/trials/nct06014190/"},{"id":"nct06112704","kind":"trial","name":"HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors","route":"/trials/nct06112704/"},{"id":"nct05367778","kind":"trial","name":"Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors","route":"/trials/nct05367778/"},{"id":"nct05435248","kind":"trial","name":"Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","route":"/trials/nct05435248/"},{"id":"nct07754123","kind":"trial","name":"Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC","route":"/trials/nct07754123/"},{"id":"nct06935409","kind":"trial","name":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","route":"/trials/nct06935409/"}]}}